Hemogenyx Pharmaceuticals (LON:HEMO) Shares Up 4.6% – What’s Next?

Hemogenyx Pharmaceuticals Plc (LON:HEMO) shares shot up 4.6% on Thursday . The stock traded as high as GBX 664 and last traded at GBX 664. 4,433 shares traded hands during trading, a decline of 81% from the average session volume of 23,279 shares. The stock had previously closed at GBX 635.

Hemogenyx Pharmaceuticals Stock Performance

The business’s fifty day moving average price is GBX 736.88 and its 200-day moving average price is GBX 828.60. The company has a debt-to-equity ratio of 167.66, a current ratio of 1.38 and a quick ratio of 6.72. The stock has a market capitalization of £40.57 million, a PE ratio of -3.50 and a beta of 1.53.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.